摘要
目的 探讨全反式维甲酸及胆酸钠对裸鼠卵巢上皮性癌动物模型干预后的正、副作用。方法 以CAOV3细胞株皮下接种BALB/C裸鼠 ,分组后分别给予不同的全反式维甲酸及胆酸钠方案用灌胃针给药进行干预 ,统一处死后留取裸鼠血、肿瘤及各重要脏器组织进行光镜、电镜及免疫组织化学检查 ,并于给药期间观察裸鼠体重及瘤体变化。结果 接种肿瘤细胞后早期行全反式维甲酸及胆酸钠干预 ,裸鼠最终肿瘤成瘤率低 ,即使成瘤需时也延长 ,肿瘤生长速度明显减慢 ;接种肿瘤细胞待成瘤后给予裸鼠行全反式维甲酸及胆酸钠干预 ,两组药物也有抑制肿瘤生长、诱导肿瘤细胞分化作用 ,而对裸鼠血相无明显抑制作用 ,对重要脏器未见明显形态学改变。结论 全反式维甲酸及胆酸钠经灌胃针用药后对荷瘤裸鼠的肿瘤确有抑制作用 ,并以早期用药为佳 。
Purpose To investigate the effects on established epithelial ovarian carcinoma bearing nude mice model after using all-trans retinoic acid and/or bile acid sodium by intragastric syringe. Methods CAOV3 cell lines were subcutaneously transplanted to BALB/C nude mice; the mice were divided into four groups by using different protocols of all-trans retinoic acid and bile acid sodium; all of tested-mice were executed and samples including blood, tumor and main organs were collected; blood routine test and pathologic examination were performed, including light microscope, electronic microscope and immunohistochemical staining; the changes of the mice weight and tumor size were observed during testing period. Results The rate of tumor formation in the early drug-used group was significantly lower; the period of tumor formation was significantly prolonged and the speed of tumor growth was relatively retarded compared with other groups. In the drug-used group after tumor formation, we found all-trans retinoic acid and bile acid sodium not only had significant tumor inhibitory effect, but also had remarkable inductive effect of tumor cell differentiation. No significant side-effect was found in the nude mice's blood and main organs. Conclusions It is evident that all-trans retinoic acid and bile acid sodium are effective to the epithelial ovarian carcinoma-bearing nude mice model, especially in the early drug using group, with no significant side-effect.
出处
《临床与实验病理学杂志》
CAS
CSCD
2004年第6期727-730,共4页
Chinese Journal of Clinical and Experimental Pathology
关键词
卵巢肿瘤
全反式维甲酸
胆酸钠
荷瘤裸鼠
卵巢上皮癌
ovarian neoplasms
all-trans retinoic acid
bile acid sodium
tumor-bearing nude mice model
epithelial ovarian carcinoma
